Article

'BioCube' searches for allergy relief

Ora Inc. is expanding its internal research efforts to include the development of a nasal allergen challenge model, as well as a new Allergen BioCube (ABC) system that can be used for evaluating anti-allergy drugs administered via both ocular and nasal routes.

Andover, MA-Ora Inc. is expanding its internal research efforts to include the development of a nasal allergen challenge model as well as a new Allergen BioCube (ABC) system that can be used for evaluating anti-allergy drugs administered via both ocular and nasal routes.

The system is a chamber-based model designed to provide a highly-controlled environment in which the mechanism of action of anti-allergy agents can be studied.

“Ora has been built upon over 30 years of the highest quality standards and scientific rigor,” said Stuart B. Abelson, president and chief executive officer of Ora. “We have used these same high standards to develop the ABC system to reproduce the signs and symptoms of allergic rhinitis in clinical trial subjects.”

According to Abelson, the company has conducted several pilot studies and validation programs to create a highly controlled environment that minimizes variability in study endpoints.

“As we expand our ABC system capabilities, we welcome companies with new chemical entities, reformulations, and line extensions to work with us on preferred terms,” he said. “The modular design of the ABC will allow us to implement future expansion plans to multiple locations to meet industry needs while maintaining the highest levels of regulatory compliance.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.